Westren Pharma Atorvastatin Calcium Tablets for Human Medicine Tablet

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: For oral administration
Gold Member Since 2020

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

QA/QC Inspectors
The supplier has 1 QA and QC inspection staff
100% Finished Products Inspection
The supplier inspects 100% of finished products.
Standardized quality control
The supplier has a complete and standardized quality control process, check the Audit Report for more information
R&D Capabilities
The supplier has 1 R&D engineers, you can check the Audit Report for more information
to see all verified strength labels (12)
  • Westren Pharma Atorvastatin Calcium Tablets for Human Medicine Tablet
  • Westren Pharma Atorvastatin Calcium Tablets for Human Medicine Tablet
Find Similar Products

Basic Info.

Model NO.
tablets
Suitable for
Elderly, Adult
State
Solid
Shape
Tablet
Type
Organic Chemicals
Pharmaceutical Technology
Chemical Synthesis
Dosage
10mg
Use
Orel
Transport Package
Box
Specification
10mg
Origin
China
Production Capacity
500000box/Month

Product Description

About
KEEP OUT OF REACH OF CHILDREN
WE CAN PROVIDE MAKE FORMEULATION (OEM)
 
 
 
Service we can provide:
1. Mixed container, we can mix different items in one container.
2. Quality control, before shipment, free sample for test. After shipment, keep sample for 3 years
3. Prompt shipment with professional documents
4. Packing as your request, with photo before shipment.
 
 
Product Name Atorvastatin Calcium Tablets
Contians Atorvastin 10mg
Package 100unit-dose/box
Store Store atorvastatin calcium tablets at 20° - 25°C (68° - 77°F)
Application Atorvastatin calcium tablet is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to: 
Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors
Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors
Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD
Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia
Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia
Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH)
Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy
   
   

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier